Mast Therapeutics (NASDAQ:SVRA) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday, January 9th.
SVRA has been the subject of several other research reports. Zacks Investment Research downgraded shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 15th. Ladenburg Thalmann Financial Services started coverage on shares of Mast Therapeutics in a research report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price target for the company. Roth Capital reissued a “buy” rating and set a $40.00 price target on shares of Mast Therapeutics in a research report on Wednesday, September 27th. Jefferies Group started coverage on shares of Mast Therapeutics in a research report on Friday, September 22nd. They set a “buy” rating and a $20.00 price target for the company. Finally, ValuEngine downgraded shares of Mast Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.58.
Mast Therapeutics (NASDAQ SVRA) traded down $0.27 on Tuesday, reaching $11.94. 296,900 shares of the company were exchanged, compared to its average volume of 201,164. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.15 and a current ratio of 9.15. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $17.19. The firm has a market cap of $372.41, a P/E ratio of -2.85 and a beta of 0.18.
Mast Therapeutics (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. analysts expect that Mast Therapeutics will post -1.64 EPS for the current year.
In other news, Director Yuri Pikover acquired 50,000 shares of Mast Therapeutics stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average cost of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the purchase, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $1,177,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.93% of the company’s stock.
WARNING: “Mast Therapeutics (SVRA) Rating Lowered to Buy at BidaskClub” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/18/bidaskclub-downgrades-mast-therapeutics-svra-to-buy.html.
Mast Therapeutics Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.